352 related articles for article (PubMed ID: 25629655)
1. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; López-Del Val A
Eur J Hosp Pharm; 2020 Nov; 27(6):355-360. PubMed ID: 33097619
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis.
Galván-Banqueri M; Vega-Coca MD; Castillo-Muñoz MA; Beltrán Calvo C; Molina López T
Farm Hosp; 2015 Mar; 39(2):80-91. PubMed ID: 25817087
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
[TBL] [Abstract][Full Text] [Related]
7. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
8. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
9. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
[TBL] [Abstract][Full Text] [Related]
10. An update on anti-TNF agents in ulcerative colitis.
Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
[TBL] [Abstract][Full Text] [Related]
11. Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
Cárdenas M; de la Fuente S; Font P; Castro-Villegas M; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérez J; Escudero-Contreras A; Casado M; Del Prado J; Collantes-Estévez E
Rheumatol Int; 2016 Feb; 36(2):231-41. PubMed ID: 26494567
[TBL] [Abstract][Full Text] [Related]
12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
[TBL] [Abstract][Full Text] [Related]
15. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
17. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.
Lofland JH; Mallow P; Rizzo J
J Med Econ; 2013; 16(4):461-7. PubMed ID: 23445401
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
[TBL] [Abstract][Full Text] [Related]
19. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
[TBL] [Abstract][Full Text] [Related]
20. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
